PARP inhibitors are actually approved in breast, ovarian, pancreatic and prostate cancers harbouring a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 (BRCA1/2) [22,23,24]. Here, BRCA2 is linked to prostate cancer.